ALLOMEK

CIP-1374 was discovered by Cheminpharma, LLC team. All intellectual property and rights related to CIP-1374 were transferred from Cheminpharma to AlloMek Therapeutics. AlloMek is a virtual company that relies on high quality Contract Research Organizations to execute experiments to further the development of its MEK program... We applied our technology to MEK1/2 kinase as a target. MEK kinase is a validated target and inhibitors of this target have application in cancer, and some of the debilitating rare diseases. With our macrocycle concept and with the help of computational modeling, we designed a series of compounds. CIP-137401, the lead molecule we chose for further development, has exhibited exceptional drug like properties and is moving along to be tested in clinical trials... AlloMek, founded in 2011, is a privately held orphan disease-focused company, developing therapeutics for catastrophic cardiomyopathy (based on discovery by Dr. Worman's group at Columbia University) and..

Primary location: Woodbridge United States